Please login to the form below

Not currently logged in
Email:
Password:

FDA recommends J&J’s stroke-prevention drug

The FDA has recommended Xarelto (rivaroxaban) for stroke prevention in patients with the heart condition nonvalvular atrial fibrillation

The Food and Drug Administration (FDA) has recommended Xarelto (rivaroxaban) for stroke prevention in patients with the heart condition nonvalvular atrial fibrillation.

Johnson & Johnson, which partnered with Bayer to develop Xarelto, had previously gained approval for its use in reducing the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.

The drug received a positive endorsement from the FDA, despite receiving a critical FDA review two days earlier.

A study into Xarelto as a stroke-prevention drug demonstrated that it was as good as other drugs currently being used. However, when switching from Xarelto to another drug, there is a spike of adverse effects, which has not been fully studied yet.

The ease of taking Xarelto (which is administered as one 20mg pill daily) compares favourably to other treatments, as neither International Normalized Ratio (INR) monitoring nor dietary restrictions are necessary.

13th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics